# Gatehouse Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gatehouse-bio

- Industry: Biotechnology
- Headquarters: Natick, US
- Website: www.gatehousebio.com
- Latest round: Seed (Dec 8, 2021)
- Investors on record: 2

## About

Based in Massachusetts, US, and founded in 2016, Gatehouse Bio, Inc., formerly known as sRNAlytics, operates as an RNA therapeutic company. The company was founded by its CEO, David Salzman, and Neal Foster. In December 2021, sRNAlytics, Inc., raised seed funding from SOSV.

Gatehouse develops various biotechnology solutions, mainly RNA therapeutics, a type of treatment that uses small RNAs (sRNAs) to target and treat a variety of diseases. The firm’s platform, Code-Breaker, utilizes artificial intelligence (AI) to find sRNAs and design biomarker-guided precision oligonucleotide therapeutics. The company develops therapies for pulmonary, cardiac, neurological, and autoimmune diseases.

## Funding rounds

- Seed, Dec 8, 2021 — SOSV
- Seed, Dec 24, 2020 — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed